This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-010328-uxpedpz8 | The re- emergence of measles in developed countries: Time to develop the next- generation measles vaccines? |
| cord-006192-bqwchhwk | Relationship to airway reactivity Bronchial circulation perfused via the pulmonary artery in guinea- pig isolated lungs Is asthma also a vascular disease? |
| cord-274150-ukdha3ap | The convalescent sera option for containing COVID-19 Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-261653-0vtghtp7 | convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-018492-d34tyar7 | Comprehensive US government program for dried plasma development Freeze dried plasma and fresh red blood cells for civilian prehospital hemorrhagic shock resuscitation Helicopter in- flight resuscitation with freeze- dried plasma of a patient with a high- velocity gunshot wound to the neck in Afghanistan-a case report Freeze- dried plasma at the point of injury: from concept to doctrine Pointof- injury use of reconstituted freeze- dried plasma as a resuscitative fluid: a special report for prehospital trauma care Prehospital administration of freeze- dried plasma, is it the solution for trauma casualties? |
| cord-352985-5ccrkfsa | The%20RECOVERY%20trial%20involves%20many%20thousands%20of%20 doctors%2C Dexamethasone for COVID-19? |
| cord-282252-07uzz649 | Once it is confirmed that the proposed donor is no longer contagious, the next step would be to see if the donor has sufficient antibody levels to donate? |
| cord-323656-bzefn894 | Drug treatment options for the 2019-new coronavirus( 2019-nCoV) Convalescent plasma: new evidence for an old therapeutic tool? |
| cord-322714-s0wge7o4 | The convalescent sera option for containing COVID-19 A serological survey on neutralizing antibody titer of SARS convalescent sera Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-326176-n0xo3e53 | What is your diagnosis? |
| cord-018142-xt71w4nr | Fresh frozen plasma transfusion or plasma exchange? |
| cord-018142-xt71w4nr | Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit( ICU) patients? |
| cord-270908-9snyt2n1 | However, what properties ofthe epithelium and what external influence could produce such a result? |
| cord-270908-9snyt2n1 | What happens to the basal cells when they loose their columnar neighbours? |
| cord-294585-dl5v9p50 | the development of haemophilia A therapeutics-from whole blood transfusion to recombinant DNA to gene therapy Sterilization of hepatitis and HTLV- III viruses by exposure to tri( n- butyl) phosphate and sodium cholate Current status of solvent/ detergenttreated frozen plasma Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura A process for solvent/ detergent treatment of plasma for transfusion at blood centers using a disposable bag system Removal of small non- enveloped viruses by nanofiltration Virus inactivation in blood components by photoactive phenothiazine dyes Methylene blue treated fresh- frozen plasma: what is its contribution to blood safety? |
| cord-319013-oytqcifa | Is it time to rethink UK restrictions on blood donation? |
| cord-031907-ilhr3iu5 | Extracellular Vesicle- based liquid biopsy in Acute Myeloid Leukaemia: a reliable source of residual disease biomarkers? |
| cord-304616-k92fa15l | Species differences in drug plasma protein binding Selective plasma protein binding of antimalarial drugs to α1-acid glycoprotein Plasma protein binding and blood- free concentrations: which studies are needed to develop a drug? |
| cord-304616-k92fa15l | What is the true clinical significance of plasma protein binding displacement interactions? |
| cord-284582-xwedgllw | But does this cfDNA have a physiological role? |
| cord-284582-xwedgllw | This raises the following question: What is the fundamental role of cfDNA in healthy organisms? |
| cord-328352-l1q4uvxl | : what do we know so far? |
| cord-328352-l1q4uvxl | The relationship between encephalitis lethargica and influenza: a critical analysis Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-280221-s6oxq772 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding The SARS, MERS and novel coronavirus( COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? |
| cord-280221-s6oxq772 | I. Infection enhancement by non- neutralizing antibody Convalescent plasma: new evidence for an old therapeutic tool? |
| cord-280221-s6oxq772 | Is COVID-19 receiving ADE from other coronaviruses? |
| cord-336177-p7b7yw28 | An augmented passive immune therapy to treat fulminant bacterial infections Position paper on use of convalescent plasma, serum or immune globulin concentrates as an element in response to an emerging virus Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-336177-p7b7yw28 | Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? |
| cord-336177-p7b7yw28 | new evidence for an old therapeutic tool? |
| cord-349031-tbof9yqi | A randomized, double- blind, placebo- controlled, multicentre trial Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS- CoV Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus( 2019-nCoV) in vitro Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open- label non- randomized clinical trial Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT- PCR A trial of lopinavir- Ritonavir in adults hospitalized with severe Covid-19 A review of the safety of favipiravir- A potential treatment in the COVID-19 pandemic? |
| cord-349031-tbof9yqi | The presence of SARS- CoV-2 RNA in the feces of COVID-19 patients Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission Presumed asymptomatic carrier transmission of COVID-19 Covid-19: Identifying and isolating asymptomatic people helped eliminate virus in Italian village Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing COVID-19 herd immunity and convalescent plasma transfer therapy High- flow nasal oxygen versus noninvasive ventilation for hypoxemic respiratory failure: Do we know enough? |
| cord-349031-tbof9yqi | Why and how? |
| cord-006860-a3b8hyyr | ( platelet count< I50/~L) or a relative decrease in platelet count(? |
| cord-006860-a3b8hyyr | The examination reveals, that Fg- Au was present in a low density on the platelet surface, in higher density in the surface connected system( SCS), in coated pits and vesicles and separated smooth vesicles( representing endosomes?) |
| cord-006860-a3b8hyyr | The superpositisn of hepatitis infections on the treatment with blood and native blood products in most of the cases has let unanswered the question related to the mechanism of the immunodeficiency: the hepatitis B or C infections or the negative impact of the itarative important alloantigenlc load? |
| cord-324908-ptlpsnfo | How do we make efficient use of convalescent plasma? |
| cord-324908-ptlpsnfo | How long after clinical resolution of symptoms is there a chance to obtain neutralization antibodies if any? |
| cord-324908-ptlpsnfo | Is clinical therapeutic effect related to antibody titer? |
| cord-324908-ptlpsnfo | Is it more likely to benefit young children and pregnant women? |
| cord-324908-ptlpsnfo | There are still some issues to consider in determining the advisability of implementing a large- scale convalescent plasma transfusion program: What is the optimal timing for infusion? |
| cord-324908-ptlpsnfo | What is the most effective frequency of administration of convalescent plasma? |
| cord-324908-ptlpsnfo | World Health Organization Convalescent plasma: new evidence for an old therapeutic tool? |
| cord-324908-ptlpsnfo | convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? |
| cord-321697-yua3apfi | : cord-321697-yua3apfi authors: Crigna, Adriana Torres; Samec, Marek; Koklesova, Lenka; Liskova, Alena; Giordano, Frank A.; Kubatka, Peter; Golubnitschaja, Olga title: Cell- free nucleic acid patterns in disease prediction and monitoring — hype or hope? |
| cord-321697-yua3apfi | Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/ serum DNA: evidence for a preferential release from viable cells? |
| cord-321697-yua3apfi | Cham: Advances in Predictive, Preventive and Personalised Medicine Mitochondrial dysfunction in the aging retina Parkinson disease epidemiology, pathology, genetics, and pathophysiology Mitochondria and autophagy dysfunction in glucocorticoidinduced ocular hypertension/ glaucoma mice model Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? |
| cord-321697-yua3apfi | Consequently, the question is- how to distinguish between beneficial physical activity on one hand and damaging exercise- induced oxidative stress on the other hand, when providing recommendations at individual level? |
| cord-321697-yua3apfi | From Phenotype to Associated Pathologies, Prediction, Prevention and Personalisation Flammer syndrome Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach Pre- metastatic niches"in breast cancer: are they created by or prior to the tumour onset Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? |
| cord-321697-yua3apfi | MicroRNAs in human diseases: from cancer to cardiovascular disease MicroRNA function in cancer: oncogene or a tumor suppressor? |
| cord-321697-yua3apfi | More answers or More confusion? MicroRNA |
| cord-321697-yua3apfi | What is known about CFNAs signature utility in COVID-19 management? |
| cord-321697-yua3apfi | Why the gold standard approach by mammography demands extension by multiomics? |
| cord-321697-yua3apfi | effective and affordable cancer care hsa- miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR Covid-19 pandemic by the"realtime"monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies COVID-19 what have we learned? |
| cord-321697-yua3apfi | primary and recurrent colorectal cancer Establishment of tumor- specific copy number alterations from plasma DNA of patients with cancer Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? |
| cord-271764-um001ffd | And for how long( in other words, is the serological neutralizing response long- lasting)? |
| cord-271764-um001ffd | Are titers of neutralizing antibodies in a recovering person high enough to enable protection in a recipient( or is there a need for preparing so- called hyperimmune immunoglobulins)? |
| cord-271764-um001ffd | At which phase of the disease to transfuse the immune plasma to best neutralize the viral replication in order to prevent tissue/ organ complications? |
| cord-271764-um001ffd | Do those persons come forwardvoluntarily and freely, in the absence of pressure, or were there external motivations such as incentives or remuneration[ 16]? |
| cord-271764-um001ffd | However, how to decipher between infected persons at- risk of manifesting complications in whom plasma therapy is sound, versus the many others who will not present with complications, in whom the exposure to plasma could cause an unnecessary risk and no or little benefit? |
| cord-271764-um001ffd | In all, what would be the best protocols, first to collect, secondly to qualify, and thirdly to apply specific plasma? |
| cord-271764-um001ffd | Last, questions arise regarding testing and qualification of donated plasma: will they be derogation of the normal rules or will restrictive qualification be applied to all donations at the expense of a potential wastage of plasma presenting an ad hoc level of antibodies but without the standard safety guarantee? |
| cord-271764-um001ffd | Next, questions arise relative to donors: can convalescent persons safely give plasma( in relatively high volume, representing an extracorporeal circulation and exposure, to non- negligible levels of calcium citrate)? |
| cord-271764-um001ffd | SARS- Cov-2? |
| cord-271764-um001ffd | Then, which protocol to apply to ensure that there is enough contact between neutralizing antibodies and the virus( and at which site)? |
| cord-271764-um001ffd | What about the evidence base and clinical trials? |
| cord-271764-um001ffd | key: cord-271764-um001ffd authors: Garraud, Olivier title: Passive immunotherapy with convalescent plasma against COVID-19? |
| cord-271764-um001ffd | um001ffd nan neutralizing antibodies- after clinical recovery of the donor? |
| cord-271764-um001ffd | why and how? |
| cord-294684-wfsdjs1f | ( IKT) compare to other collaborative research approaches to generating and translating knowledge? |
| cord-294684-wfsdjs1f | ( IKT) evidence base: colloquium proceedings and research direction Lost in knowledge translation: time for a map? |
| cord-294684-wfsdjs1f | ; donor responsibilities Should men who have ever had sex with men be allowed to give blood? |
| cord-294684-wfsdjs1f | A systematic mapping review Developing and evaluating complex interventions: the new Medical Research Council guidance How do people become plasma and platelet donors in a VNR context? |
| cord-294684-wfsdjs1f | Are you in a mutually exclusive( monogamous) relationship? |
| cord-294684-wfsdjs1f | As of 2019, all male donors are asked'In the last 3 months, have you had sex with another man?' |
| cord-294684-wfsdjs1f | Context and social perceptions of blood donation in donors found positive for human immunodeficiency virus in France Should men who have ever had sex with men be allowed to give blood? |
| cord-294684-wfsdjs1f | Have you had sex with more than one partner in the last 3 months? |
| cord-294684-wfsdjs1f | No Is there a right to donate blood? |
| cord-294684-wfsdjs1f | The additional behavioural questions under consideration include: 1 Have you had sex with a new partner in the last 3 months? 2 |
| cord-294684-wfsdjs1f | What can qualitative research do for randomised controlled trials? |
| cord-294684-wfsdjs1f | gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100 M website views per year submit your research? |
| cord-294684-wfsdjs1f | relaxes rules for gay blood donors amid coronavirus- will Canada go further? |
| cord-294684-wfsdjs1f | the relationship between real and hypothetical moral choices An end to lifetime blood donation ban in Israel for MSM would be a major step toward a science- based policy that reduces stigma Blood donation deferral policies among men who have sex with men in Brazil Men having sex with men and blood donation: is there a game changer on the horizon? |